07.09.2021 15:48:39
|
Illumina Partners With Merck To Develop Tests For Use In Identifying Specific Cancer Mutations
(RTTNews) - Illumina Inc. (ILMN) and Merck & Co Inc. (MRK) have partnered to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency or HRD, Illumina said in a statement.
Patients whose tumors are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina's TruSight Oncology 500 content.
Illumina noted that the partnership builds on an initial study conducted with Merck and leverages Illumina's relationship with Myriad Genetics (MYGN) to expand international access to the proprietary technology in Myriad's FDA approved myChoice CDx companion diagnostic test.
Illumina said it will develop a new HRD CDx test for the EU and the UK to aid in the identification of ovarian cancer patients with positive HRD status who are eligible for treatment with LYNPARZA or olaparib, a first-in-class PARP inhibitor, jointly developed and commercialized by Merck and AstraZeneca.
In addition, Illumina will develop and commercialize a research use only HRD assay that will be add-on content for the TruSight Oncology 500 RUO panel. Illumina plans to launch this product globally, excluding the United States and Japan.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
07.03.25 |
Impulsarmer Handel in New York: Dow Jones pendelt zum Start des Freitagshandels um seinen Schlusskurs vom Donnerstag (finanzen.at) | |
06.03.25 |
Börse New York: Dow Jones fällt schlussendlich zurück (finanzen.at) | |
04.03.25 |
Dow Jones aktuell: Dow Jones mittags in Rot (finanzen.at) | |
04.03.25 |
Dow Jones 30 Industrial-Titel Merck-Aktie: So viel hätten Anleger mit einem Investment in Merck von vor 5 Jahren verdient (finanzen.at) | |
04.03.25 |
Minuszeichen in New York: Dow Jones zum Start des Dienstagshandels im Minus (finanzen.at) | |
03.03.25 |
Verluste in New York: Dow Jones fällt zum Ende des Montagshandels zurück (finanzen.at) | |
27.02.25 |
Börse New York in Rot: Dow Jones schlussendlich im Minus (finanzen.at) | |
26.02.25 |
Schwacher Handel: Dow Jones fällt schlussendlich zurück (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Illumina Inc. | 77,90 | -1,00% |
|
Merck Co. | 86,30 | -0,46% |
|
Myriad Genetics Inc. | 9,55 | -2,05% |
|